Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Rating of "Hold" from Brokerages

Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) has received an average recommendation of "Hold" from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold rating. The average twelve-month price target among brokers that have covered the stock in the last year is $2.51.

A number of research analysts recently issued reports on AKYA shares. Piper Sandler dropped their price objective on shares of Akoya Biosciences from $2.40 to $1.65 and set a "neutral" rating for the company in a report on Monday, April 14th. Stephens reiterated an "equal weight" rating and issued a $1.80 price objective (down previously from $3.50) on shares of Akoya Biosciences in a report on Tuesday, March 25th. Finally, Canaccord Genuity Group dropped their price objective on shares of Akoya Biosciences from $1.80 to $1.08 and set a "hold" rating for the company in a report on Monday, May 19th.

Institutional Trading of Akoya Biosciences

Several large investors have recently modified their holdings of the stock. Deutsche Bank AG lifted its holdings in shares of Akoya Biosciences by 404.1% in the 4th quarter. Deutsche Bank AG now owns 54,788 shares of the company's stock worth $125,000 after purchasing an additional 43,920 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Akoya Biosciences by 18.9% in the 4th quarter. Northern Trust Corp now owns 250,343 shares of the company's stock worth $573,000 after purchasing an additional 39,799 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Akoya Biosciences in the 4th quarter worth $31,000. Paragon Associates & Paragon Associates II Joint Venture lifted its holdings in shares of Akoya Biosciences by 1.4% in the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 801,000 shares of the company's stock worth $1,834,000 after purchasing an additional 11,000 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Akoya Biosciences by 295.4% in the 4th quarter. JPMorgan Chase & Co. now owns 48,313 shares of the company's stock worth $111,000 after purchasing an additional 36,093 shares in the last quarter. Institutional investors and hedge funds own 79.42% of the company's stock.

Akoya Biosciences Stock Down 3.1%

AKYA stock opened at $1.26 on Monday. The stock has a market capitalization of $62.94 million, a P/E ratio of -1.30 and a beta of 1.35. The company has a current ratio of 0.61, a quick ratio of 0.40 and a debt-to-equity ratio of 10.12. Akoya Biosciences has a 12 month low of $0.93 and a 12 month high of $3.42. The firm has a 50-day moving average price of $1.19 and a 200-day moving average price of $1.80.

Akoya Biosciences (NASDAQ:AKYA - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.03). The company had revenue of $16.64 million during the quarter, compared to the consensus estimate of $20.19 million. Akoya Biosciences had a negative return on equity of 487.85% and a negative net margin of 59.44%. As a group, equities research analysts anticipate that Akoya Biosciences will post -0.96 EPS for the current fiscal year.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.